本文選題：BDNF + Ets-1　； 參考：《青島大學(xué)》2017年碩士論文

【摘要】：目的:該研究主要是進(jìn)一步論證與卵巢癌侵襲轉(zhuǎn)移相關(guān)的BDNF、Ets-1這兩個(gè)基因蛋白在上皮性漿液性卵巢癌的表達(dá)情況與臨床病理特征之間的關(guān)系及兩者之間的相關(guān)性。研究BDNF、Ets-1在上皮性漿液性卵巢癌的發(fā)生及發(fā)展關(guān)系。方法:通過(guò)免疫組化及Western Blot方法檢測(cè)BDNF、Ets-1這兩個(gè)基因蛋白在上皮性漿液性卵巢癌石蠟切片及新鮮卵巢組織中的表達(dá)情況,分析BDNF、Ets-1與臨床病理特征(臨床分期、分化程度、淋巴結(jié)轉(zhuǎn)移、遠(yuǎn)處轉(zhuǎn)移、年齡等)的關(guān)系,及進(jìn)一步研究?jī)煞N基因蛋白在上皮性漿液性卵巢癌中表達(dá)的相關(guān)性。結(jié)果:1.BDNF在正常卵巢組織中的的陽(yáng)性表達(dá)率為15%,在交界性卵巢組織中陽(yáng)性表達(dá)率為40%,在上皮性漿液性卵巢癌的陽(yáng)性表達(dá)率為67%,主要位于細(xì)胞質(zhì)中,由此可見(jiàn)在惡性卵巢組織中的陽(yáng)性表達(dá)率最高,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。2.BDNF在漿液性卵巢癌中的表達(dá)與臨床分期(P=0.001)、有無(wú)遠(yuǎn)處轉(zhuǎn)移(P=0.004)、有無(wú)淋巴結(jié)轉(zhuǎn)移(P=0.000)及組織分化程度(P=0.044)有關(guān),差異有統(tǒng)計(jì)學(xué)意義,(P0.05),與年齡無(wú)明顯關(guān)系(P0.05)。BDNF在臨床分期晚期、有遠(yuǎn)處轉(zhuǎn)移、有淋巴結(jié)轉(zhuǎn)移、組織分化程度低組中呈高表達(dá)。BDNF在臨床分期早期、無(wú)遠(yuǎn)處轉(zhuǎn)移、無(wú)淋巴結(jié)轉(zhuǎn)移、組織分化程度高組中表達(dá)水平低。3.Ets-1在卵巢良性組織中陽(yáng)性表達(dá)率為22%,在交界性卵巢組織中陽(yáng)性表達(dá)率為44%,在上皮性漿液性卵巢癌組織中陽(yáng)性表達(dá)率為50%,主要位于細(xì)胞間質(zhì)中,少量位于細(xì)胞核中�？梢钥闯�,Ets-1在三種不同卵巢組織中表達(dá)情況存在明顯差距,三組之間X2=2.0,P=0.000,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。4.Ets-1在漿液性卵巢癌中的表達(dá)與臨床分期(P=0.024)、有無(wú)遠(yuǎn)處轉(zhuǎn)移(P=0.000)、有無(wú)淋巴結(jié)轉(zhuǎn)移(P=0.003)及組織分化程度(P=0.001)有關(guān),差異有統(tǒng)計(jì)學(xué)意義,(P0.005),與年齡無(wú)明顯關(guān)系(P0.05)。Ets-1在臨床分期晚期、有遠(yuǎn)處轉(zhuǎn)移、有淋巴結(jié)轉(zhuǎn)移、組織分化程度低組中呈高表達(dá)。Ets-1在臨床分期早期、無(wú)遠(yuǎn)處轉(zhuǎn)移、無(wú)淋巴結(jié)轉(zhuǎn)移、組織分化程度高組中表達(dá)水平低或幾乎無(wú)表達(dá)。5.經(jīng)過(guò)Spearman相關(guān)性分析,在上皮性漿液性卵巢癌組織中BDNF表達(dá)強(qiáng)度增加,Ets-1表達(dá)強(qiáng)度也增加,且隨著卵巢癌惡性程度的增加,BDNF、Ets-1兩個(gè)基因蛋白表達(dá)也增加,P=0.041,兩者在上皮性漿液性卵巢癌組織的表達(dá)成正相關(guān)(r=0.447,P0.05)。結(jié)論:1.BDNF、Ets-1這兩個(gè)基因蛋白在上皮性漿液性卵巢癌組織中高表達(dá),且隨著惡性程度的增加,表達(dá)水平也升高,說(shuō)明BDNF、Ets-1可能參與了卵巢癌的發(fā)生及發(fā)展過(guò)程。2.BDNF、Ets-1表達(dá)水平與卵巢癌患者的預(yù)后因素有關(guān),說(shuō)明BDNF、Ets-1可能影響患者的預(yù)后。抑制這兩個(gè)基因蛋白的表達(dá)將來(lái)可能成為治療卵巢癌的一個(gè)重要的治療方法。3.經(jīng)過(guò)Spearman相關(guān)性分析,在上皮性漿液性卵巢癌組織中BDNF表達(dá)強(qiáng)度增加,Ets-1表達(dá)強(qiáng)度也增加,且隨著卵巢癌惡性程度的增加,BDNF、Ets-1兩個(gè)基因蛋白表達(dá)也增加,兩者在上皮性漿液性卵巢癌組織的表達(dá)成正相關(guān)。
[Abstract]:Objective: This study is to further demonstrate the relationship between the expression of BDNF, Ets-1 and the clinicopathological features of the two gene proteins associated with the invasion and metastasis of ovarian cancer, and the relationship between them and the relationship between them. The relationship between the development and development of BDNF and Ets-1 in epithelial serous ovarian cancer is studied. Methods: Immunohistochemical and Western Blot methods were used to detect the expression of BDNF, Ets-1, two gene proteins in the paraffin and fresh ovarian tissues of epithelial serous ovarian cancer, and to analyze the relationship between BDNF, Ets-1 and clinicopathological features (clinical stage, differentiation, lymph node metastasis, distant migration, age, etc.), and further study the two kinds of gene eggs. The positive expression rate of 1.BDNF in normal ovarian tissue was 15%, the positive expression rate in the borderline ovarian tissue was 40%, the positive expression rate in epithelial serous ovarian cancer was 67%, mainly in the cytoplasm, thus the positive form in the malignant ovarian tissue was found. The difference was statistically significant (P0.05), the expression of.2.BDNF in serous ovarian cancer and clinical stage (P=0.001), distant metastasis (P=0.004), lymph node metastasis (P=0.000) and the degree of tissue differentiation (P=0.044), the difference was statistically significant, (P0.05), and there was no significant relationship with age (P0.05).BDNF in the late stage of clinical stage. The positive expression rate of.BDNF in the benign tissue of the ovary was 22%, the positive rate in the borderline ovarian tissue was 44%, and the positive expression rate in the borderline ovarian tissue was 44%, in the epithelial serous sex. The positive expression rate in ovarian cancer tissues was 50%, mainly in the cytoplasm and a small amount in the nucleus. It can be seen that the expression of Ets-1 in three different ovarian tissues has a significant difference, and the difference between the three groups is X2=2.0 and P=0.000, the difference is statistically significant (P0.05), the expression of.4.Ets-1 in the serous ovarian cancer and the clinical stage (P=0.024). No distant metastasis (P=0.000) was associated with lymph node metastasis (P=0.003) and the degree of tissue differentiation (P=0.001). The difference was statistically significant, (P0.005), and there was no significant relationship with age (P0.05).Ets-1 in the late stage of clinical stage, with distant metastasis, lymph node metastasis, and high expression of.Ets-1 in the low level of tissue differentiation in the early stage of clinical staging and no distant transition. The expression of BDNF in the epithelial serous ovarian cancer tissues increased and the expression of Ets-1 increased, and the expression of Ets-1 was increased with the increase of the malignant degree of ovarian cancer, and the expression of two gene proteins in BDNF and Ets-1 increased with the increase of the malignant degree of ovarian cancer, and the expression of two gene proteins in BDNF and Ets-1 also increased, P=0.041, The expression of the two in epithelial serous ovarian cancer tissue is positive correlation (r=0.447, P0.05). Conclusion: 1.BDNF, Ets-1 these two gene proteins are highly expressed in epithelial serous ovarian cancer tissue, and with the increase of the malignant degree, the expression level is also elevated, indicating that BDNF, Ets-1 may be involved in the development and development of ovarian cancer.2.BDNF, Ets-1 Expression level is associated with prognostic factors in ovarian cancer patients, indicating that BDNF, Ets-1 may affect the prognosis of patients. Inhibition of the expression of these two gene proteins may become an important treatment for ovarian cancer in the future,.3. after Spearman correlation analysis, the increase of BDNF expression in epithelial serous ovarian cancer, Ets-1 table With the increase of the malignant degree of ovarian cancer, the expression of the two gene proteins of BDNF and Ets-1 also increased, which was positively related to the expression of epithelial serous ovarian cancer.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 劉微;畢芳芳;楊清;;Ets-1與卵巢惡性腫瘤關(guān)系的研究進(jìn)展[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年16期

2 郝長(zhǎng)宏;田永會(huì);劉正玲;許宗蘭;;Ets-1和HIF-1α蛋白在子宮內(nèi)膜癌中的表達(dá)及臨床意義[J];現(xiàn)代婦產(chǎn)科進(jìn)展;2016年03期

3 周立莉;葛新國(guó);蔡茂懷;唐峰;朱建峰;孫林;李霞;劉菊林;王彩蓮;;非小細(xì)胞肺癌中ETS-1與E-cadherin、N-cadherin、Vimentin表達(dá)相關(guān)性的研究[J];癌癥進(jìn)展;2015年05期

4 薛成軍;陳治水;袁蓉;陳輝;;PEA3亞家族在乳腺癌中的研究進(jìn)展[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2013年05期

5 于曉輝;蔡斌;楊懿霞;嚴(yán)沁;萬(wàn)小平;;酪氨酸激酶受體B在OVCAR-3卵巢癌細(xì)胞中的表達(dá)及意義[J];中國(guó)癌癥雜志;2008年06期

6 Paul Hertzog;Trevor J Wilson;;Ets1 as a marker of malignant potential in gastric carcinoma[J];World Journal of Gastroenterology;2003年10期

7 嚴(yán)瑞蘭,辛?xí)匝?王健,王德堂;CD44v6在上皮性卵巢腫瘤中的表達(dá)及臨床意義[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2002年05期

，

本文編號(hào)：2030655